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Visual hallucinations in Alzheimer's disease
do not seem to be associated with chronic
hypoperfusion of to visual processing areas
V2 and V3 but may be associated with
reduced cholinergic input to these areas
Lindsey Isla Sinclair1,2* , Amit Kumar3, Taher Darreh-Shori 3 and Seth Love2
Abstract
Background: Up to 20% of patients with AD experience hallucinations. The pathological substrate is not known.
Visual hallucinations (VH) are more common in dementia with Lewy bodies (DLB). In autopsy studies, up to 60% of
patients with AD have concomitant Lewy body pathology. Decreased perfusion of the occipital lobe has been
implicated in DLB patients with VH, and post-mortem studies point to both decreased cholinergic activity and
reduced oxygenation of the occipital cortex in DLB.
Methods: We used biochemical methods to assess microvessel density (level of von Willebrand factor, a marker of
endothelial cell content), ante-mortem oxygenation (vascular endothelial growth factor, a marker of tissue hypoxia;
myelin-associated glycoprotein to proteolipid protein-1 ratio, a measure of tissue oxygenation relative to metabolic
demand), cholinergic innervation (acetylcholinesterase and choline acetyltransferase), butyrylcholinesterase and
insoluble α-synuclein content in the BA18 and BA19 occipital cortex obtained post-mortem from 23 AD patients
who had experienced visual hallucinations, 19 AD patients without hallucinations, 19 DLB patients, and 36 controls.
The cohorts were matched for age, gender and post-mortem interval.
Results: There was no evidence of reduced microvessel density, hypoperfusion or reduction in ChAT activity in AD
with visual hallucinations. Acetylcholinesterase activity was reduced in both BA18 and BA19, in all 3 dementia
groups, and the concentration was also reduced in BA19 in the DLB and AD without visual hallucinations groups.
Insoluble α-synuclein was raised in the DLB group in both areas but not in AD either with or without visual hallucinations.
Conclusions: Our results suggest that visual hallucinations in AD are associated with cholinergic denervation rather than
chronic hypoperfusion or α-synuclein accumulation in visual processing areas of the occipital cortex.
Keywords: Dementia, Alzheimer’s disease, Visual hallucinations, Vascular endothelial growth factor, Myelin-associated
glycoprotein, PLP1, von Willebrand factor, Acetylcholine, Post-mortem tissue
Introduction
Alzheimer’s disease (AD) is the most common form of
late-life dementia. Its incidence is set to nearly triple by
2050, due to the ageing of the population [1]. As with all
dementias, it has a devastating effect on patients and
those around them. The pathological hallmarks of AD
are neurofibrillary tangles and amyloid-β plaques. Up to
20% of patients with AD experience hallucinations dur-
ing their illness [2]. Current treatments for this can be
ineffective, and antipsychotics are often used, which in-
crease the risk of stroke and premature death [3].
Visual hallucinations can be very distressing for both
patients and their relatives. They occur in most forms of
dementia but are particularly common in dementia with
Lewy bodies (DLB) [4]. The core pathology in DLB is
the accumulation of α-synuclein in Lewy bodies and
Lewy neurites [5]. In autopsy studies, up to 60% of
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: eplis@bristol.ac.uk
1Population Health Sciences, Oakfield House, University of Bristol, Clifton,
Bristol BS8 2BN, UK
2Translational Health Sciences, Level 1 Learning & Research Building,
Southmead Hospital, University of Bristol, Bristol BS10 5NB, UK
Full list of author information is available at the end of the article
Sinclair et al. Alzheimer's Research & Therapy           (2019) 11:80 
https://doi.org/10.1186/s13195-019-0519-7
patients with AD had at least some concomitant Lewy
body pathology [4]. Several studies have found that vis-
ual hallucinations are more likely in those with AD and
Lewy body pathology [6–9]. One large study suggested
that there was an AD plus Lewy body phenotype con-
sisting of dementia with delusions, hallucinations and
prominent motor problems [10].
Most of the work on the pathophysiology of visual hal-
lucinations in dementia has been in DLB. Neuroimaging
studies have shown decreased perfusion of the occipital
lobe, a region of the cortex with only sparse Lewy bodies
[11–13]. A PET study found reduced fluorodeoxyglucose
uptake in the occipital cortex of individuals with DLB
who had visual hallucinations [14]. A SPECT study
which compared DLB to AD found reduced perfusion in
the medial occipital lobe in DLB but not in AD [15]. In-
deed reduced occipital lobe perfusion is now included as
a supportive biomarker for the diagnosis of DLB [16].
Post-mortem studies have suggested decreased choliner-
gic activity in the visual cortex in DLB [17] and de-
creased oxygenation of the occipital cortex in DLB,
which correlated with reduced microvessel density and
was associated with decreased VEGF [18].
Acetylcholinesterase inhibitors such as donepezil have
been shown to reduce visual hallucinations in DLB, al-
though they do not help all patients [19]. A small uncon-
trolled study showed that donepezil increased occipital
lobe perfusion on SPECT and decreased hallucinations
[20]. Work in myocytes has suggested an intriguing dir-
ect link between cholinergic stimulation and VEGF level
[21]. It is also known that cholinergic stimulation causes
vasodilatation [22].
Current theories of the basis of visual hallucinations in
dementia include the perception and attention deficit
model, which proposes a lack of integration of incoming
sensory information and top-down prior knowledge/ex-
pectation [23]. It has advantages over other models, e.g.
the misidentification model, in that it better accounts all
of the observed phenomena in different disease states.
This model implicates the ventral visual stream in the re-
current complex visual hallucinations seen in DLB as this
stream is more involved in object-based attention. It has
been suggested that cholinergic input modulates the inter-
action between bottom-up perceptions and top-down pro-
cessing and also modulates the level of certainty of top-
down information. The authors suggested that cholinergic
deficits lead to over-processing of top-down information
leading to visual hallucinations [24]. An imbalance be-
tween serotonin and acetylcholine (ACh) has also been
implicated in visual hallucinations [25].
We set out to determine whether visual hallucinations
in AD result from Lewy body pathology or chronic hypo-
perfusion affecting the visual processing areas in the oc-
cipital cortex. Given that acetylcholinesterase inhibitors
reduce visual hallucinations (at least to some extent) and
the suggestion of a direct link between cholinergic input
and vessel profusion, we also assessed cholinergic input,
by measuring the 3 enzymes involved in the production
and breakdown of ACh (see Fig. 1). We previously dem-
onstrated that the ratio of the hypoxia-sensitive myelin-as-
sociated glycoprotein (MAG) to the hypoxia-resistant
proteolipid oprotein-1 (PLP) is a robust measure of ante-
mortem perfusion in relation to metabolic demand [26,
27]. Both myelin proteins are very stable under post-mor-
tem conditions [26] and have half-lives of several months.
A decline in the MAG:PLP1 ratio in post-mortem brain
tissue reflects a reduction in ante-mortem oxygenation of
the tissue over a period of several months prior to death.
von Willebrand factor is a marker of microvessel (capil-
lary) density, and VEGF is upregulated in hypoperfused
tissue [18, 26–28]. We previously showed that VEGF and
capillary density are reduced in the primary visual cortex
in DLB [18].
In view of the evidence of reduced perfusion in the oc-
cipital lobes in patients with visual hallucinations, and the
theoretical implication of visual processing areas in the oc-
cipital cortex, we decided to focus on V2 (BA18) and V3
(BA19). After V1 (BA17), the visual processing pathway
splits into ventral and dorsal pathways (see Fig. 2). In the
present study, we have assessed the ventral pathway, as
this is postulated to be concerned with “what” is seen ra-
ther than the “where” that is processed via the dorsal path-
way. There is evidence to suggest that the ventral pathway
is more likely to be involved in visual hallucinations in
DLB [23, 29].
We hypothesised that the occipital cortex from AD
patients with visual hallucinations would show evidence
of reduced perfusion as measured by the MAG:PLP1 ra-
tio in V2 and V3 compared to controls and to AD pa-
tients without visual hallucinations.
Methods
The study used brain tissue and clinical data obtained
from the South West Dementia Brain Bank (SWDBB),
University of Bristol, with local Research Ethics Commit-
tee approval (REC reference 18/SW/0029). Comprehen-
sive clinical summaries are recorded in the SWDBB
database for all brain donors. The summaries are gener-
ated from the patient medical notes and from any add-
itional information collected as part of the Brains for
Dementia Research Programme. The summaries were
searched using the following terms: psychosis, hallucin-
ating, hallucinations, quetiapine, risperidone and visual.
This allowed us to identify 24 individuals with neuro-
pathologically confirmed AD who had definitely experi-
enced visual hallucinations and 33 individuals with AD
who had definitely not experienced visual hallucinations
during their illness. We also selected 23 individuals with
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neuropathologically confirmed dementia with Lewy bod-
ies, 2 of whom had not and 21 who had experienced vis-
ual hallucinations, and 36 controls without dementia.
We excluded individuals who had had major vascular
abnormalities or vascular dementia as a primary diagno-
sis. Psychiatric, neurological and treatment histories for
the individuals in this cohort are summarised in Add-
itional file 1: Table S3. The cohorts were matched for
age, gender and post-mortem interval. Braak tangle stage
and severity of arteriolosclerotic small vessel disease and
cerebral amyloid angiopathy had been assessed as de-
scribed [26, 30].
Dementia was assessed clinically using DSM-IV criteria
[31], and DLB was diagnosed according to consensus
neuropathological criteria [4]. The right half of each brain
had been fixed in formalin for 3 weeks prior to the detailed
neuropathological examination, and the left half sliced and
subdivided into multiple samples which were frozen at −
80 °C. Neuropathological diagnoses of AD were made ac-
cording to NIA-AA criteria [32]. Control individuals had
no history of cognitive problems or psychosis during their
lifetime and had no major neuropathological abnormalities
on post-mortem examination other than mild
neurofibrillary tangle pathology (Braak stage ≤ 3) or scat-
tered diffuse Aβ plaques (see Table 1 for a summary of the
characteristics of the cohorts). The cases selected for the
dementia with Lewy bodies group had only “low AD neuro-
pathologic change” which according to NIA-AA criteria
[32] would not have accounted for dementia.
Homogenate preparation
Fresh frozen tissue was dissected from ventral BA18 and
BA19 from the left occipital lobe. To produce the SDS
homogenates used for most of the assays in this project,
200 mg of tissue was homogenised in 1 ml of chilled 1%
SDS lysis buffer in a Precellys tissue homogeniser (2 ×
15 s at 6000g) with 6–10 zirconia beads in a 2-ml hom-
ogenate tube. The homogenates were then centrifuged
for 15 min at 13,000g at 4 °C. The supernatant was ali-
quoted into non-binding 96-well storage plates (Thermo
Scientific) and frozen at − 80 °C until required.
Choline acetyltransferase (ChAT) homogenates were
prepared using a method adapted from that of Peng et
al. [33]. Fifty to 100 mg of fresh frozen tissue was placed
in a 2-ml homogenate tube with 6–10 zirconia beads.
The volume of all buffers in microlitres added was
Fig. 1 Acetylcholine (ACh) is synthesised by choline acetyltransferase (ChAT) and broken down by acetylcholinesterase (AChE) at low concentrations
and butyrylcholinesterase (BChE) at higher concentrations
Fig. 2 The visual processing pathways in the brain. Ventral visual area V2 is shown in purple (BA18) and ventral visual area V3 is shown in yellow
(BA19). Figure from the OpenStax Anatomy & physiology textbook 2014 CCBY 3.0, available
from https://cnx.org/contents/FPtK1zmh@12.16:KcreJ7oj@9/Central-Processing
Sinclair et al. Alzheimer's Research & Therapy           (2019) 11:80 Page 3 of 15
calculated as 15× the tissue weight in milligrams. Buffer
A was 50mM potassium phosphate, 2 mM EDTA, pH
7.4. Buffer B was 50 mM potassium phosphate, 2 mM
EDTA, 500 mM NaCl, pH 7.4. Buffer C was 50mM po-
tassium phosphate, 2 mM EDTA, 0.6% triton X-100, pH
7.4. After each buffer was added, the tissue was homoge-
nised for 2 × 15 s at 6000g in a Precellys tissue homogen-
iser and then spun for 30 min at 28,000×g at 4 °C. The
homogenisation was started with buffer A. The super-
natant was removed, and the tissue re-homogenised and
then re-centrifuged in the subsequent buffers. In this
way, the fractions extracted were soluble ChAT (buffer
A), ionic membrane-bound ChAT (buffer B) and mem-
brane-bound ChAT (buffer C). The total ChAT homog-
enates used in the assays described below were prepared
by adding equal volumes of each supernatant, e.g. 200 μl
supernatant A plus 200 μl supernatant B plus 200 μl
supernatant C. As no protease inhibitors were used in
the sample preparation, the whole operation was carried
out with the samples either on ice or at 4 °C. The sam-
ples were aliquoted out (100 μl per tube) and frozen at
− 80 °C until required. The reason for omitting protease
inhibitors cocktail in the buffers is that one or several of
these inhibitors also irreversibly inhibit the cholinergic
enzymes (personal observations by TDS) and thereby
would interfere with the downstream enzyme activity
assessments.
The soluble and insoluble extracts used for the α-sy-
nuclein assays were prepared in a third buffer. Up to
200 mg of tissue was homogenised in 1 ml of chilled
TBS extraction buffer with 1% NP-40 (pH 7.4) in a Pre-
cellys tissue homogeniser (2 × 15 s at 6000g) with 6–10
zirconia beads in a 2-ml homogenate tube. The homoge-
nates were then centrifuged for 15 min at 13,000g at
4 °C. The supernatants were removed and aliquoted into
non-binding 96-well storage plates (Thermo Scientific)
and frozen at − 80 °C until required. The pellet was re-
suspended in 400 μl of guandicine HCl buffer (3 parts
guanidine HCl to 1 part 50 mM Tris, pH 8), homoge-
nised again in a Precellys tissue homogeniser (2 × 15 s at
6000g) and then spun for 15 min at 13,000g at 4 °C. The
supernatant was removed, aliquoted onto non-binding
96 well storage plates (Thermo Scientific) and frozen at
− 80 °C until required. Total protein was measured for
all samples with a Coomassie Protein Plus kit (Thermo
Scientific).
Vascular endothelial growth factor ELISA
VEGF was measured using a commercial kit (R&D Sys-
tems Duoset DY293B) adapted for use in a 384-well
Nunc MaxiSorp plate. Seventy-five microlitres of mouse
anti-human VEGF capture antibody, diluted 1:120 in
PBS, was added to each well. The plate was then sealed
and incubated overnight at room temperature. Following
Table 1 Characteristics of the study cohort. Small vessel disease and cerebral amyloid angiopathy scoring were performed on a 4-
point scale [26, 30]. Although the cohorts were matched for age, gender and post-mortem interval, there was weak evidence of a
between-group difference in age at death. Analyses were therefore carried out both with and without age as a covariate
AD with visual
hallucinations,
n = 23
AD without
visual hallucinations,
n = 19
Dementia
with Lewy bodies,
n = 19
Controls,
n = 36
Statistical findings p with age as
covariate
Mean SD Mean SD Mean SD Mean SD
Age (years) 76.7 9.0 79.3 9.0 81.0 7.0 82.1 6.3 ANOVA p = 0.065
Post-mortem interval (h) 36.7 21.1 41.8 16.3 33.3 18.1 36.9 15.6 ANOVA p = 0.533
Age at onset of dementia
(years)
66.9 10.4 66.4 10.1 73.0 6.9 N/A N/A Kruskal-Wallis p = 0.164, χ2 =
3.611
Duration of dementia
(years)
9.7 4.2 11.1 3.4 7.6 4.6 N/A N/A ANOVA p = 0.04 0.0340
Mean Braak stage 5.5 0.5 5.3 0.9 3.1 1.5 2.0 0.8 χ2 = 109.9, p < 0.001
Cerebral amyloid angiopathy score
0 3 3 9 24 χ2 = 31.37, p < 0.001
1 7 3 3 3
2 7 8 2 3
3 6 4 5 3
Occipital small vessel disease score
0 2 2 3 8 χ2 = 8.07, p = 0.527
1 11 6 5 10
2 6 3 1 6
3 0 2 1 1
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4 × 3-min washes with 0.05% PBS/Tween per well, the
plate was blocked by adding 100 μl 1% BSA/PBS to each
well and was incubated for 1 h at 26 °C with agitation.
After a further 4 × 3min with 110 μl 0.05% PBS/Tween
per well, the samples, standards and blanks were added
in triplicate. The samples were diluted 1:10 in 1% BSA/
PBS and 50 μl added to each sample well. Blanks were
50 μl of 1% BSA/PBS. Standards were prepared in line
with the manufacturer’s instructions, and 50 μl was
added to each well. The plate was incubated for 2 h at
26 °C with agitation. After a further 4 washes, 75 μl of bi-
otinylated goat anti-human VEGF detection antibody
(diluted 1:60 in 1% BSA/PBS) was added to each well,
and the plate then incubated for 2 h at 26 °C plus agita-
tion. After a further 4 washes, 75 μl of streptavidin HRP
diluted 1:40 in PBS/0.05% Tween was added to each well
and the plate incubated for 20 min in the dark at room
temperature. After a final 4 washes, 50 μl of the sub-
strate was added to each well, and 25 μl of STOP solu-
tion was added after 20 min. Absorbance was read at
450 nm. The intraclass correlation coefficient for this
assay was 0.89, indicating excellent consistency.
Myelin-associated glycoprotein ELISA
MAG was measured by indirect ELISA which was devel-
oped in-house [26, 27]. Autoclaved PBS was used through-
out this assay. Samples were diluted 1:10 in autoclaved PBS
and loaded in duplicate onto a 96-well Nunc MaxiSorp
ELISA plate. Blanks consisted of 100 μl of PBS and stan-
dards (Abcam ab89780) ranged from 547.6 to 8.56 ng/ml.
The plate was incubated for 2 h at 26 °C with agitation.
After 5 washes in PBS/0.05% Tween, the plate was blocked
by adding 300 μl of 1%BSA/PBS per well and incubated for
1 h at 26 °C with agitation. After a further 5 washes, 100 μl
of mouse monoclonal anti-MAG antibody (Abcam
ab89780) diluted 1:1000 in PBS was added to each well.
The plate was incubated for 2 h at 26 °C with agitation.
After a further 5 washes, 100 μl of biotinylated anti-mouse
antibody (Vector, diluted 1:4000 in PBS) was added to each
well, and the plate incubated for 20min at 26 °C with agita-
tion. After a further 5 washes, 100 μl of streptavidin-HRP
diluted 1:500 in PBS/0.01% Tween was added to each well
and the plate incubated for 20min at 26 °C with agitation.
After a final 5 washes, 100 μl of the substrate was added to
each well and 50 μl of STOP solution added after 10min.
Absorbance was read at 450 nm. The intraclass correlation
coefficient for this assay was 0.60, indicating good
consistency. All samples were assayed in duplicate on each
plate and on two different plates.
PLP ELISA
PLP was assayed using a commercial sandwich ELISA
kit (Cloud-Clone Corporation), as per the manufac-
turer’s instructions. Samples were diluted 1:10 for this
assay. Three samples were carried over on each plate to
check that the results were consistent.
von Willebrand factor (vWF) dot blot
Samples were initially centrifuged again for 20 min at 15,
000 rpm to remove any particulate matter then diluted
1:400 in TBS. The standard was 7 serial dilutions of a
reference homogenate, starting with a dilution of 1:100
in TBS. Prior to assembling the dot blot manifold, the
membrane was soaked in TBS for at least 10 min. One
hundred microlitres of each sample was loaded onto the
membrane after it had been placed in the dot blot vac-
uum manifold and was incubated for 75 min. The mani-
fold was then disassembled and the membrane washed
for 3 × 10 min in TTBS prior to blocking in 5% milk/
TBS for 1 h at room temperature with agitation. After a
further 3 × 10-min washes in TTBS, the membrane was
incubated overnight at 4 °C with agitation, in rabbit poly-
clonal anti-vWF antibody (Dako A0082) diluted 1:3000
in 5% milk/TTBS. Following 3 × 30-min washes, the
membrane was incubated in HRP conjugated goat anti-
rabbit antibody (Vector) diluted 1:5000 in 5% milk/TTBS
for 1 h at room temperature with agitation. After a fur-
ther 3 × 30-min washes, 6 ml of the substrate was added
to each membrane, and after 4 min, it was imaged in a
BioRad imager (chemiluminescence protocol). All sam-
ples were assayed in duplicate on each membrane and
on two different membranes. The intraclass correlation
coefficient for this assay was 0.69, indicating good
consistency.
Alpha-synuclein ELISA
Alpha-synuclein was measured in soluble and insoluble
extracts by ELISA developed in-house, as described pre-
viously, adapted for use in a 384-well Nunc MaxiSorp
plate [34, 35]. The mouse monoclonal capture antibody
(BD Biosciences) was diluted 1:1000 in PBS and 75 μl
added to each well and left overnight at room
temperature. After 5 washes in PBS/0.05% Tween, the
plate was blocked by adding 100 μl of 1% BSA/PBS to
each well and incubating the plate at room temperature
for 70 min with agitation. After a further 5 washes, the
samples, 7 serial twofold dilutions of recombinant pro-
tein standard (R peptide S-100-1) and blanks were
loaded, 50 μl per well in duplicate. The concentration of
the standards ranged from 62.5 to 0.98 ng/ml. The sam-
ples were diluted 1:400 in PBS, and the blanks consisted
of 50 μl PBS. The plate was incubated at room
temperature for 90 min plus agitation. After a further 5
washes, 70 μl of biotinylated polyclonal antibody (R&D
systems BAF1338), diluted 1:600 in 1% BSA/PBS, was
added to each well and the plate incubated for 90 min at
room temperature with agitation. After a further 5
washes, 75 μl of streptavidin-HRP diluted 1:200 in PBS/
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0.05% Tween was added to each well and the plate incu-
bated for 20 min in the dark at room temperature with
agitation. After a final 5 washes, 50 μl of the substrate
was added to each well, and 25 μl of STOP solution was
added after 20 min. Absorbance was read at 450 nm.
Measurement of ChAT, AChE and BChE
ChAT activity was assayed using an assay designed by
Dr. Darreh-Shori’s group at the Karolinska Institutet, as
previously described in detail [36]. The assay was per-
formed on 384-well plates. The wells were coated over-
night at 4 °C with 100 μl of monoclonal anti-ChAT
(R&D systems MAB3447) diluted 1:250 in 1× coating
buffer per well except for wells which would later be
used for the choline standards. After 5 washes with TBS,
the samples (both native and denatured), standards and
blanks were loaded. Samples were denatured by incuba-
tion at 99 °C for 3 × 8min 30 s in a PCR machine. Ten
microlitres of each sample was loaded in triplicate.
Blanks consisted of dilution buffer alone. The reference
standard for ChAT concentration was a pooled brain
homogenate which had been prepared with 10× vol of
each buffer. There were 7 × 2-fold dilutions of the
pooled homogenate, starting with a dilution of 1:2. The
choline standards for ChAT activity consisted of 8 × 2-
fold dilutions of choline, with choline standard C1 =
50 μM. Fifty microlitres of each choline standard was
loaded in triplicate. Forty microlitres of cocktail A was
added to each sample/pooled homogenate/blank well.
cocktail A was prepared as 4× of final concentrations
and contained 10 μM choline chloride, 50 μM acetyl-
CoA, 7 mM acetyl phosphate and 1 unit/ml phosphoace-
tyltransferase (to continuously regenerate acetyl-CoA
from –CoA generated by ChAT) in TBS buffer.
The plate was then incubated for 1 h at 38.5 °C with
gentle agitation. After this, 25 μl of cocktail B was added
to each well including those containing the choline stan-
dards, and the plate was immediately read at 500 nm, at
1 min interval for 1 h, using the kinetic mode of a Tecan
M1000 spectrophotometer. The cocktail B contained 2.1
mM phenol, 1 mM 4-aminoantipyrine, 0.31 units/ml
choline oxidase and 1/15,000 streptavidin HRP in 10
mM PBS, pH 7.6.
The plate was then sealed and left overnight at 4 °C.
The next day, the plate was read again at 500 nm prior
to 3 × 5-min washes in TBS/0.05% Tween. One hundred
microlitres of TBS/0.05% Tween/5% BSA/0.1% sodium
azide was loaded into each well, and the plate was incu-
bated for 30 min at 38 °C with gentle agitation. After a
further 3 washes, 100 μl of polyclonal anti-ChAT anti-
body (Abnova PAB14536) diluted 1:3500 in TBS/0.05%
Tween/1% BSA/0.01% sodium azide was loaded per well,
and the plate was incubated for 1 h at 38 °C with gentle
agitation. After a further 3 washes, 75 μl of polyclonal
swine anti-rabbit AP diluted 1:1750 in TBS/0.05%
Tween/1% BSA/0.01% sodium azide was loaded per well,
and the plate incubated for 30 min at 38 °C with agita-
tion. After a further 4 washes in TBS/0.05% Tween and
one wash in diethanolamine buffer (0.022% DEA, 50mM
MgCl2, pH 9.8), 75 μl of AP substrate (para-nitrophenol,
1 mg/ml) was loaded into each well, and the plate was
read at 405 nm, with a reference absorbance of 650 nm.
The absorbance was read immediately, at 1 h, 2 h and
the next morning.
AChE and BChE assays were performed using a
modified version of Ellman’s colorimetric assay adapted
to a high-throughput assay as described previously [37,
38]. Briefly, 384-well Nunc MaxiSorp plates (Merck)
were coated O/N at 4 °C with 75 μl of 1:1000 HR2
(anti-AChE monoclonal antibody; Thermo Fisher) and
1:2000 diluted 3E8 Ab17246 in carbonate buffer pH 9.5,
(anti-BChE monoclonal antibody; Abcam) for AChE
and BChE assays, respectively. The next day, the plates
were emptied and washed three times with TBS (50
mM Tris-Cl, pH 7.5 and 150 mM NaCl) buffer followed
by blocking with carbonate buffer pH 9.5, containing
5% BSA for 1 h at room temperature (RT). Afterwards,
the plates were washed three times with TBS buffer
containing 0.05% Tween-20 (TBS-T) and 25 μl of stan-
dards, and samples from ventral BA18 and the left oc-
cipital lobe BA19 were added in triplicate to the
assigned wells. For standards, the human recombinant-
AChE (S1-S8 with 2 times serial dilution starting from
200 ng/ml; Sigma-Aldrich, C1682) and human-BChE
(S1-S8 with 2 times serial dilution starting from 34.3
ng/ml; Sigma-Aldrich, C9971) were used. Next, 50 μl of
master mix prepared in Na/K phosphate buffer, con-
taining final concentrations of 0.5 mM acetylthiocholine
iodide (ATC) or 5 mM butyrylthiocholine iodide (BTC),
0.4 mM 5,5′-dithiobis (2-nitrobenzoic acid) (DTNB)
and 0.1 mM ethopropazine (BChE inhibitor) or 1 μM
BW284c51 (AChE inhibitor; Sigma-Aldrich, A9013),
were added to the AChE and BChE assay plate wells.
The plates were read at 412 nm for 30 min with 2-min
interval cycle using a microplate spectrophotometer
reader (Infinite M1000, Tecan) to measure AChE and
BChE activity (ΔOD/min).
For AChE and BChE protein concentration estimation,
an ELISA-like functional assay was used. Briefly, the
plates were sealed following activity measurement and
incubated for 2–3 h at RT. After incubation, the plates
were washed two times with TBS-T buffer and read
again at 412 nm for 60 min with 5-min interval cycle
after adding master mix containing final concentrations
of 0.5 mM ATC or 5 mM BTC and 0.4 mM DTNB. The
protein levels of AChE and BChE in the samples were
then determined from the linear part of the standard
curves as described before [39].
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Formalin-fixed tissue preparation
The right cerebral hemisphere of each brain had been
fixed for 3–4 weeks in formalin prior to being dissected
into blocks and embedded in wax. The paraffin sections
of the occipital cortex containing both BA18 and BA19
were cut at 7 μM thickness. Immunolabelling for alpha-
synuclein was performed in an automated immunostai-
ner. The mouse monoclonal anti α-synuclein antibody
(Vector VP-A106) was diluted 1:800 and applied for 1 h
prior to DAB development of the slides.
The field fraction immunopositive for each antigen
was assessed by examining up to 15 random fields of
BA18 and BA19 under a × 20 objective. The software
package Image-Pro Plus (Media Cybernetics, MD, USA)
was used to select the fields at random in the pre-de-
fined area and for image capture. For a small number of
slides, the area of BA18/19 included in the section was
too small to accommodate 15 non-overlapping fields,
but at least 10 were captured in all cases.
Statistical analysis
All ELISAs were adjusted for total protein content. This
was done using the following formula:
Adjusted result ¼ sample target protein concentration
sample total protein concentration
All data were analysed using parametric statistical tests
such as ANOVA wherever possible. If a variable was not
normally distributed and it was not possible to achieve a
normal distribution by transformation, non-parametric
tests were used such as the Kruskal-Wallis test. The pri-
mary outcome measure was whether the MAG:PLP1 ra-
tio varied between the groups. For field fraction analysis,
each field on each slide was given equal weighting, and
mean values were compared by ANOVA, with age, gen-
der and post-mortem interval as covariates. For a priori
analyses, any demographic variable which varied be-
tween groups (e.g. age, post-mortem interval) was in-
cluded as a covariate. Where Dunn’s test was used,
Bonferroni correction was applied. A threshold p value
of 0.05 was used throughout.
We estimated, using the information from a previous
study [18], that we would have 89% power to detect a
between-group difference in the MAG:PLP1 ratio of
0.07.
Results
Tissue was obtained from a total of 97 individuals for
both BA18 (visual processing area 2) and BA19 (visual
processing area V3): 23 with AD and a history of visual
hallucinations, 19 individuals who had Alzheimer’s dis-
ease who had not suffered from visual hallucination, 19
individuals who had dementia with Lewy bodies (either
with or without visual hallucinations) and 36 controls.
The groups were matched for age, gender and post-mor-
tem interval, although the AD + visual hallucinations
group was marginally younger than the other groups
(p = 0.065). As would be expected, the AD groups had a
higher Braak stage than the other groups, and there was
a between-group difference in cerebral amyloid angiopa-
thy score, with both AD groups scoring higher [30]. Al-
though the initial ANOVA was suggestive of a difference
between the groups in disease duration, there was little
evidence of a difference in the subsequent regression.
As shown in Additional file 1: Table S2, the clinical
diagnosis during life frequently differed from the neuro-
pathological diagnosis. This was more likely for the AD
with visual hallucinations and dementia with Lewy body
groups. The rate of change of diagnosis was similar to
other post-mortem series [40, 41].
Because of the marginal difference in age between the
groups, parametric analyses were carried out both with
and without age as a covariate to exclude the confound-
ing effect of a difference in age as the explanation for
any between-group differences observed.
As can be seen in Table 2 and Fig. 3, there was no
strong evidence of a between-group difference in VEGF,
MAG, PLP1 or vWF. There was no evidence of a be-
tween-group difference in MAG:PLP1 in BA19, but un-
expectedly, MAG:PLP1 seemed to be increased in all
three dementia groups in BA18. There was only statis-
tical evidence of a between-group difference between the
two AD groups (p = 0.029). As expected from previous
studies, MAG:PLP1 correlated negatively with VEGF
(see Additional file 1: Figure S1) [18].
There was no evidence of a between-group difference
in ChAT activity (Table 3, Additional file 1: Figure S3).
AChE activity was reduced in all three dementia groups
in both BA18 and BA19, as shown in Fig. 4. AChE con-
centration was unchanged in BA18 but was decreased in
the AD with visual hallucinations and DLB groups in
BA19. There was no evidence of a between-group differ-
ence in either BChE activity or concentration (see Add-
itional file 1: Figure S4). ChAT activity, AChE and BChE
were relatively stable with disease duration (Add-
itional file 1: Figure S6). There was no evidence of a
change in the ratio of cholinergic breakdown to produc-
tion enzymes (known as the cholinergic index), as shown
in Additional file 1: Figure S5.
Removing controls with a history of mental health
problems, stroke or TIAs reduced the number of con-
trols to 16. The findings in relation to AChE, BChE and
ChAT were unchanged when these controls were ex-
cluded. The evidence for a between-group difference in
MAG to PLP ratio in BA18 in the opposite direction to
that predicted weakened considerably, but this did not
affect our overall conclusion that there was no strong
Sinclair et al. Alzheimer's Research & Therapy           (2019) 11:80 Page 7 of 15
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evidence of hypoperfusion in the occipital lobes of those
with AD and visual hallucinations.
Field fraction analysis yielded no evidence of a between-
group difference in immunolabelled α-synuclein, but most
of the values were very small (see Fig. 5 and Add-
itional file 1: Table S4). Measurement of soluble and insol-
uble fractions by ELISA showed that insoluble α-synuclein
was increased in the DLB group in BA18 and 19 com-
pared to both AD groups, as would be expected. In both
brain areas, although the initial ANOVA was suggestive of
a between-group difference in soluble α-synuclein, this
was not shown in the subsequent regression.
Discussion
In this relatively large post-mortem study of AD and
DLB, we did not find any strong evidence of occipital
hypoperfusion or α-synuclein accumulation in the tissue
from AD patients with visual hallucinations. There was
evidence of derangement of the cholinergic equilibrium
in AD and DLB: a reduction in acetylcholinesterase ac-
tivity most marked in AD with visual hallucinations, but
no change in the ChAT activity.
It is well known that cholinergic innervation is lost in
AD [42], although the occipital lobe seems to be rela-
tively spared compared to the other brain regions [43]. It
was originally thought that this loss of cholinergic neu-
rons occurred earlier in AD than in DLB, but more re-
cent work suggests the converse [44]. The temporal
cortex may be affected earlier than the other brain areas
in AD. Tiraboschi et al. [44] found cholinergic loss to be
greatest in the superior temporal cortex in mild AD, less
in the inferior parietal and the medial frontal cortex not
to be affected until moderate-severe stages of the dis-
ease. Cholinergic innervation to the occipital lobe from
the nucleus basalis of Meynert was shown to be dis-
rupted in Parkinson’s disease, with increasing
Fig. 3 There was no between-group difference in MAG:PLP1 in BA19 (b), but all three dementia groups seemed to have increased MAG:PLP1 in
BA18 (a). There was no convincing between-group difference in VEGF in either BA 18 (c) or BA19 (d) or in vWF in BA18 (e). There was some
evidence that vWF was increased in the AD + VH group in BA19 (f)
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cholinergic neuronal loss with the progression of the
disease [45].
Several studies have shown that cholinergic innerv-
ation of neurons in the occipital cortex influences visual
attention and responses [46–48], and it is not surprising
therefore that deficient cholinergic input might influence
visual processing. The cholinergic activity also has the
potential to influence visual processing indirectly,
through its actions on the vasculature. Work in mice has
demonstrated that donepezil can promote angiogenesis
(by increasing HIF-1 alpha and VEGF) [21]. A study in
human endothelial cells had similar findings, but only
when ACh acted via muscarinic and not nicotinic recep-
tors [49]. It is also known that cholinergic stimulation
causes vasodilatation, although in some situations ACh
is involved in vasoconstriction [22, 50, 51]. It is therefore
possible, but not yet proven, that cholinergic denervation
may reduce perfusion of the affected brain areas [52, 53].
Visual hallucinations have also been shown to occur
earlier in DLB than in AD [54]. Visual hallucinations are
rare in MCI but become more common in all-cause
early dementia [55]. One large study based in a specialist
early AD clinic found very low rates of VH, and the au-
thors commented that VH seemed to be more prevalent
in the later stages of the illness [56], perhaps reflecting
cholinergic denervation in areas of the cortex affected
later on than the temporal lobe. EEG slowing in AD and
visual hallucinations was interpreted as a potential
neurophysiological indicator of cholinergic deficiency
[57].
Our finding of no between-group difference in ChAT
activity is in contrast to the findings of another group, in
a smaller study which studied BA18/19 as a single sam-
ple. They found ChAT activity to be reduced in BA17
and BA18/19 in both DLB and AD, but with a larger re-
duction in DLB [17]. Our current study had similar
Braak stages and longer disease duration than the previ-
ous study, so these factors cannot explain the different
results. Our study used a different method for measuring
ChAT activity and was also larger (particularly the con-
trol group), which may account for the discrepant find-
ings. One explanation for the lack of difference in ChAT
activity is that astrocytes are able to express ChAT on
demand and this may mask a reduction in neuronal
ChAT that might be caused by cholinergic neurodegen-
eration [36].
Although AChE hydrolyses acetylcholine more quickly
than BChE, AChE is inhibited at higher concentrations
of ACh. BChE is not and works more efficiently at
higher concentrations. Both enzymes need to be
Fig. 4 Acetylcholine breakdown enzymes. AChE activity was reduced in all three dementia groups in BA18 (a) and BA19 (b). AChE concentration
was decreased in the AD with VH and DLB groups in BA19 (d) but was unaltered in BA18 (c). VH, visual hallucinations
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measured to assess the changes in cholinergic function
[58]. As there was no between-group difference in BChE,
our results suggest that any differences in the cholinergic
activity are occurring at lower concentrations of the
neurotransmitter. Many of the patients would have taken
AChE inhibitors, but it would be expected that such in-
hibition would, if anything, lead to an increase in AChE
rather than a decrease [59]. In support of our results,
AChE activity was found to be reduced by 27% in a
small PET study of patients with DLB and Parkinson’s
disease dementia, especially in the medial occipital cor-
tex [60].
A previous study by our group found evidence of
chronically reduced oxygenation of primary visual
cortex in DLB and evidence that this was due to re-
duced microvessel density rather than vasoconstric-
tion [18]. This is important as cholinergic innervation
of the blood vessels is thought to play a role in regu-
lating cerebral blood flow by causing vasodilatation
[22]. In rats, cholinergic projections from the basal
forebrain have been shown to release ACh and cause
vasodilation when activated [61]. As in our previous
study on BA17 (primary visual cortex), MAG was
slightly reduced in BA18 and BA19 in the DLB group
compared to controls, although the statistical evidence
for this was very weak. The MAG:PLP1 ratio was not
measured in our previous study. In the present study,
VEGF was raised in the DLB group, whereas it was
decreased in our previous study. The differences may
relate to the differences between the specific areas of
the visual cortex that were assessed, but it is also
noteworthy that the present study was considerably
larger, the DLB and control groups both being dou-
bled in size.
We found no between-group difference in the (very
low) α-synuclein field fraction in the occipital cortex but
evidence of increased insoluble α-synuclein in the DLB
group in both BA18 and BA19. This is entirely in keep-
ing with work by Khundakar et al. and our own group
[18, 62]. Khundakar et al. also did not demonstrate any
Fig. 5 a–f Results of α-synuclein ELISAs and field fraction analysis. There was no strong evidence of a between-group difference in soluble α-
synuclein. There was increased insoluble α-synuclein in the DLB group compared to both AD groups, but the DLB group did not differ statistically
from controls. VH, visual hallucinations
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difference between DLB, AD and controls in capillary
density in the visual cortex.
Strengths of our present study are the relatively large
number of individuals with AD and DLB as well as the
size of the control cohort. The assays yielded consistent
data, giving us confidence in our results. The main
weakness of this study is our reliance on the retrospect-
ive collection of data on the presence or absence of vis-
ual hallucinations. We measured indirect markers of
chronic hypoperfusion, but our previous studies have
shown these measures to be reliable markers of hypoper-
fusion in several diseases and under a wide range of
post-mortem conditions. The study was limited to se-
lected visual processing areas in the ventral occipital cor-
tex. Future studies should assess other visual processing
areas, including V4–V6. Other brain areas that have
been associated with visual hallucinations, including the
superior colliculus and the cuneus, should also be con-
sidered [63, 64].
Conclusion
In conclusion, this relatively large post-mortem brain tis-
sue study did not show evidence of more severe α-synu-
clein pathology or chronic hypoperfusion in the ventral
visual processing areas V2 and V3 in AD with visual hal-
lucinations, compared to AD without visual hallucina-
tions or controls. There was also no difference in the
ChAT activity. However, AChE activity was reduced in
DLB and AD and particularly so in AD with visual
hallucinations.
Additional file
Additional file 1: Figure S1. As can be seen, MAG:PLP1 correlated
negatively with VEGF, although the relationship was relatively weak.
Figure S2. ChAT concentration. There was no between-group difference
in ChAT concentration in either BA18 (A) or BA19 (B). VH = visual
hallucinations. Figure S3. ChAT activity. There was no significant
between-group difference in ChAT activity in either brain area. Figure
S4. Neither BChE activity nor concentration differed between the groups
in either brain area. There was little relationship between either AChE or
BChE activity and protein concentration, suggesting that some of the
enzyme present was inactive. Figure S5. Examining the relationship
between ChAT activity and the activity of cholinergic breakdown
enzymes. The cholinergic index in A and B was calculated as ChAT
activity/AChE activity + BChE activity. In C and D, the ration of ChAT
activity to AChE activity alone is shown. Figure S6. Cholinergic markers
and disease duration. ChAT activity (A and B), AChE activity (C and D)
and BChE activity (E and F) activity did not change significantly with
disease duration. Table S1. α-Synuclein results. Table S2. Comparison
between diagnosis in life and the pathological diagnosis made post-
mortem. The most common diagnosis listed in the other dementia
column was unspecified “dementia” or “senile dementia”. Table S3.
Further details on medical history for the
individuals whose donated tissue was used in this study. The “other
neurological diagnoses” included epilepsy late on in dementia (3 people),
minor head injuries, vascular Parkinsonism (1 person) and possible SLE
(1 person). It was apparent that some individuals were treated with
antipsychotics to control distress at the end of their lives, rather than to
treat psychotic symptoms. (DOCX 772 kb)
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